A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 917 participants.

Also called NCT04093752

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 917 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04093752
Other papers using this trial's data
  • Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial Nature medicine, 2023-06 DOI, PubMed 37231074

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia, China, India, South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04093752. Randomized; no masking; primary purpose treatment. Start 2019-12-09 (actual); primary completion 2021-11-01 (actual). Results posted on 2023-01-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo)
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Insulin Glargine
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct04093752
Content hash
64f26170d877f55f7b13796d6324f2ae84467613e8dcfe83ac8f9d1f5e67884c